Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Acquisition

According to a recent LinkedIn post from BioSpectator Inc, Novartis is pursuing a major next-generation IgE opportunity by agreeing to acquire Excellergy and its Phase 1 asset Exl-111 in a deal reportedly valued at about $2 billion. The post notes this move follows mounting U.S. biosimilar competition to Novartis’s blockbuster Xolair and the long-running clinical failure of its previous follow-on candidate ligelizumab.

The company’s LinkedIn post highlights that Excellergy, which reportedly raised a $70 million Series A round last year, is being acquired at an early stage shortly after starting first patient dosing in a Phase 1 trial in February. The post indicates that Exl-111 recently showed preclinical data in non-human primates suggesting near-complete removal of receptor-bound IgE, potentially differentiating it from agents that primarily target free IgE.

According to the post, Novartis is emphasizing Exl-111’s mechanism that rapidly and effectively dissociates IgE already bound to FcεRIα receptors, in contrast to existing IgE therapies designed to suppress circulating free IgE. If clinical results validate this mechanism, investors may view the asset as a way for Novartis to rebuild and possibly extend its IgE franchise beyond Xolair in the face of biosimilar erosion.

The post also situates this transaction within broader industry activity, pointing to GSK’s roughly $2.2 billion acquisition of RAPT Therapeutics in January for a long-acting Xolair-like program. This pattern of high-value deals around early-stage IgE assets suggests large pharmaceutical companies are willing to pay strategic premiums to secure potential successor products in allergic and immunologic diseases.

For investors tracking the IgE and broader immunology markets, the activity described in the LinkedIn post may signal rising competition and valuation benchmarks for differentiated mechanisms in this space. While clinical and regulatory risks for Exl-111 remain significant at the Phase 1 stage, the deal size and competitive context could support higher expectations for innovation-driven M&A across early-stage biotech focused on next-generation IgE modulation.